Biodistribution of dual radiolabeled lipidic nanocapsules in the rat using scintigraphy and γ counting

被引：29

作者：

Cahouet, A ^{[1
]}

Denizot, B ^{[1
]}

Hindré, F ^{[1
]}

Passirani, C ^{[1
]}

Heurtault, B ^{[1
]}

Moreau, M ^{[1
]}

Le Jeune, JJ ^{[1
]}

Benoît, JP ^{[1
]}

机构：

[1] INSERM, ERITM Ingn Vectorisat Particulaire 0104, F-49100 Angers, France

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2002年 / 242卷 / 1-2期

关键词：

biodistribution; LiPidic nanocapsules; radiolabeling; technetium-99m; iodine-125; scintigraphy;

D O I：

10.1016/S0378-5173(02)00218-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aim of the present work was to study the biodistribution of a radiolabeled lipidic nanocapsule formulation after intravenous administration in rat by scintigraphy and gamma counting. This formulation is expected to be used as anticancer agent delivery devices and as transfection complexes. For this purpose, Tc-99m-oxine was incorporated in the lipidic core, while I-125 labeled tensioactive shell of the nanocapsule. First, in vitro stability of radiolabeled nanocapsules was evaluated by dialysis against distilled water and size measurements. Second, the nanocapsule biodistribution was followed after intravenous administration for 3 h by dynamic scintigraphic acquisition and up to 24 h by determining the gamma activity in blood and tissues. Radiolabeling was efficient and stable in vitro. After intravenous injection blood radioactivity decreased with an early half disappearance time of about 45 min for both radioisotopes. Liver and intestine radioactivities raised up to 24 h. The relatively long remanence in blood of the tracers which is probably due to the presence of PEG at the nanocarrier surface seems promising for the use of these solvent free lipidic nanocapsules as carrier of lipophilic drugs. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

页码：367 / 371

页数：5